BiotechTube

ITF2357

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Impairment

Conditions

Hepatic Impairment

Trial Timeline

May 28, 2025 → Aug 13, 2025

NCT ID
NCT06736223

About ITF2357

ITF2357 is a phase 1 stage product being developed by Biotrial for Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT06736223. Target conditions include Hepatic Impairment.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06736223Phase 1Completed

Competing Products

20 competing products in Hepatic Impairment

See all competitors
ProductCompanyStageHype Score
GB1211 + PlaceboComac MedicalPhase 1/2
33
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
28
OlomorasibEli LillyPhase 1
33
SimufilamCassava SciencesPhase 1
25
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
DS-3201bDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
PexidartinibDaiichi SankyoPhase 1
33
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
33
BocidelparAstellas PharmaPhase 1
33
fezolinetantAstellas PharmaPhase 1
33
enzalutamideAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP2215Astellas PharmaPhase 1
33
BPN14770ShionogiPhase 1
33
S-217622ShionogiPhase 1
33
LemborexantEisaiPhase 1
33
LenvatinibEisaiPhase 1
33

Other Products from Biotrial

EXS21546Phase 1/2
33
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)Phase 1/2
33
LPH-5 + PlaceboPhase 1
25
Binimetinib Oral TabletPhase 1
25
VNA-318 + PlaceboPhase 1
25